Anbio Biotechnology NNNN
Set alert
3.60 USD +0.24 +7.14%
As of Nov 2, 11:22 AM ET
3.42 Day range 3.60
3.09 52-week range 44.73
- YTD
- -88.03%
- 1 year
- -78.64%
- Open
- 3.42
- Prev close
- 3.36
- Mkt cap
- 158.01M
- Vol
- 11.36K
- Avg vol
- 151.59K
- EPS
- 0.15
- P/E
- 24.00
- Div yield
- 0.00%
More statistics
- Low
- 3.42
- High
- 3.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 1.79
- Inst. own
- 4.90%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 22.29
- 200-d avg
- 25.98
- 1y target
- 0.00
2Y chart
Signals (57)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 4 weeks ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Sep 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| RSI: Oversold | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 9, 2026 | 3 months ago |
| RSI: Oversold | Jun 29, 2026 | 4 months ago |
| RSI: Oversold | Jun 24, 2026 | 4 months ago |
| RSI: Oversold | Jun 16, 2026 | 4 months ago |
| RSI: Oversold | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| SMA: Bullish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| MACD: Sell Signal | May 6, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 11, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bearish | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 16, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Dec 4, 2025 | 11 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 11, 2025 | 11 months ago |
| RSI: Oversold | Oct 31, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 24, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 17, 2025 | 1 year ago |
| RSI: Oversold | Oct 2, 2025 | 1 year ago |
| RSI: Oversold | Sep 26, 2025 | 1 year ago |
| RSI: Oversold | Sep 23, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Aug 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| RSI: Overbought | Jun 3, 2025 | 1 year ago |
| RSI: Overbought | May 20, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | May 8, 2025 | 1 year ago |
Key statistics
- Market cap
- 412.14M
- Enterprise value
- 400.24M
- Trailing P/E
- 62.60
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 47.66
- Price / book
- 13.67
- EPS (TTM)
- 0.15
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 74.06%
- Revenue (TTM)
- 8.65M
- Revenue growth
- 73.90%
- Free cash flow
- -9.61M
- Total cash
- 11.90M
- Total debt
- 0
- Return on equity
- 27.05%
- Shares outstanding
- 43.89M
- Short % of float
- 0.20%
- 50-day average
- 22.29
- 200-day average
- 25.98
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NNNN Revenue — annual 8.65M
NNNN Net income — annual 6.40M
NNNN EPS — annual 0.147
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Germany
- Website
- anbiobiotechnology.com
News
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Top 3 Health Care Stocks That May Rocket Higher In July
- Top 3 Health Care Stocks That May Rocket Higher In July
- Top 3 Health Care Stocks You'll Regret Missing In Q2
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review
Your note
Sign in to keep a note on NNNN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.06% | 25,763 | 241.91K | Mar 30, 2026 |
| BNP Paribas Financial Markets | 0.02% | 10,400 | 97.66K | Mar 30, 2026 |
| Morgan Stanley | 0.02% | 7,338 | 68.90K | Mar 30, 2026 |
| UBS Group AG | 0.01% | 6,339 | 59.52K | Mar 30, 2026 |
| Blue Trust, Inc. | 0.00% | 5 | 46 | Mar 30, 2026 |
| Wells Fargo & Company | 0.00% | 100 | 939 | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 26,736 | 251.05K | May 30, 2026 |